MAPT and Alzheimer disease: Although there is more interest in the development of disease-modifying anti-amyloid or anti-tau drugs, as noted above, cholinesterase inhibitors are still considered valid drugs in the current scenario of AD treatments (Molchan and Fugh-Berman, 2023).